<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Renal pathology and <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> commonly coexist </plain></SENT>
<SENT sid="1" pm="."><plain>Treatments that lower <z:mp ids='MP_0002871'>albuminuria</z:mp>/<z:hpo ids='HP_0000093'>proteinuria</z:hpo> may lower <z:chebi fb="23" ids="18059">lipids</z:chebi>, but it is not known whether <z:chebi fb="23" ids="18059">lipid</z:chebi> lowering independent of lessening <z:mp ids='MP_0002871'>albuminuria</z:mp>/<z:hpo ids='HP_0000093'>proteinuria</z:hpo> <z:hpo ids='HP_0003677'>slows progression</z:hpo> of <z:e sem="disease" ids="C0022658" disease_type="Disease or Syndrome" abbrv="">kidney disease</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>We examined the association between <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> levels and treatment with <z:chebi fb="0" ids="6541">losartan</z:chebi> on <z:hpo ids='HP_0003774'>end-stage renal disease</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="23" ids="18059">Lipid</z:chebi> levels and <z:mp ids='MP_0002871'>albuminuria</z:mp> measurements were obtained at baseline and at year 1 in a post hoc analysis from the Reduction of Endpoints in <z:mp ids='MP_0002057'>NIDDM</z:mp> with the <z:chebi fb="0" ids="2719,48432">Angiotensin II</z:chebi> <z:chebi fb="68" ids="48706">Antagonist</z:chebi> <z:chebi fb="0" ids="6541">Losartan</z:chebi> (RENAAL) study, which compared the effects of <z:chebi fb="0" ids="6541">losartan</z:chebi>- versus placebo-based <z:chebi fb="0" ids="35674">antihypertensive</z:chebi> therapy in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> lowering was associated with a lower risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e>; however, this seemed to be largely an association with the reduction in <z:mp ids='MP_0002871'>albuminuria</z:mp> </plain></SENT>
</text></document>